Browse the evidence

Caloric restriction triggers adaptive thermogenesis, including reduced BMR/RMR, hormonal shifts (lowered T3, leptin, increased ghrelin), and increased appetite, which persist long-term and contribute to weight regain.

When you restrict calories, your body fights back by lowering your metabolic rate and increasing hunger hormones. This is a survival mechanism, not a personal failing. To manage this, consider strategies that preserve muscle mass, manage stress, and perhaps use precision nutrition to mitigate these adaptive responses.

Sustained lockdown-induced sedentary behavior and dietary shifts in healthy adults cause significant worsening of cardiovascular risk factors, including increased BMI, body fat, LDL cholesterol, blood glucose, and blood pressure.

Maintain physical activity and monitor dietary intake during periods of restricted movement. The study shows that even healthy adults experience measurable declines in metabolic health (weight, lipids, glucose) when sedentary, highlighting the need for proactive lifestyle management during lockdowns or similar restrictions.

Mandatory menu calorie labeling in US chain restaurants reduces cardiovascular disease and type 2 diabetes incidence, generating net healthcare and societal cost savings.

Support and comply with menu calorie labeling laws. While individual behavior change is modest, the population-level effect prevents thousands of heart attacks and diabetes cases, saving billions in healthcare costs.

Cotadutide, a dual GLP-1 and glucagon receptor agonist, significantly reduces urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and chronic kidney disease compared to placebo, with effects sustained over 26 weeks.

If you have type 2 diabetes and early kidney disease, cotadutide (a daily injection) significantly reduces albumin in your urine, a key marker of kidney health. This effect is seen at higher doses (300-600 mg) and is sustained over time. It works on top of your current medications. While it causes some GI side effects, these are generally manageable and similar to other GLP-1 drugs. Discuss with your doctor if this dual-agonist approach is right for you, especially if you are not getting enough kidney protection from current treatments.

During weight-loss maintenance, a high-carbohydrate diet (60% energy) significantly reduces late postprandial circulating energy availability compared to a low-carbohydrate diet (20% energy), primarily by suppressing free fatty acids.

If you are maintaining weight loss, be aware that high-carbohydrate meals may reduce the amount of fat available for your body to burn in the hours after eating, primarily due to insulin effects. This doesn't mean you will gain weight if you stay in a calorie deficit, but it may make you feel less energetic or hungrier later if your body is relying on stored fat. Experiment with lower carbohydrate ratios (e.g., 20-40%) to see if it improves your satiety and energy stability.

Obesity is an independent risk factor for the onset and progression of chronic kidney disease (CKD), with visceral adiposity and fatty kidney disease serving as key pathophysiological mediators.

Maintaining a healthy weight is critical for kidney health. Excess visceral fat directly harms kidney function through inflammation and blood pressure changes. Weight management is a primary strategy to prevent or slow kidney disease.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and reduce albuminuria, offering potential kidney protection, though their direct impact on eGFR decline in normal-functioning kidneys is not yet fully established.

GLP-1 medications like semaglutide help with weight loss and have been shown to reduce albuminuria (a sign of kidney stress). They are a promising option for kidney protection, especially for those with diabetes and obesity.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) improve liver histology in MASH patients, with semaglutide demonstrating the strongest evidence for resolving steatohepatitis without worsening fibrosis.

If you have MASH, GLP-1 medications like semaglutide are currently the most evidence-backed pharmacological option to improve liver health, potentially resolving the disease without worsening scarring. This is particularly relevant if you also have Type 2 Diabetes or obesity, as these drugs address the underlying metabolic drivers. While weight loss contributes, the histological benefits appear to extend beyond weight reduction alone.

Liraglutide (1.8 mg) improves liver enzymes and reduces hepatic steatosis in MASH patients, though its ability to resolve NASH histology is modest compared to semaglutide.

Liraglutide 1.8 mg can significantly lower liver enzymes (ALT/AST) and reduce liver fat in MASH patients. However, it is less effective than semaglutide at fully resolving the inflammation (NASH) itself, so it may be a good option for enzyme control but less so for complete histological reversal.

Resistance training performed to volitional failure induces microvascular expansion (increased capillary-to-fiber ratio, capillary contacts, and capillary-to-fiber perimeter exchange index) regardless of whether the load is high (75-90% 1RM) or low (30-50% 1RM).

If you want to improve the blood supply to your muscles, you don't need to lift heavy weights. As long as you perform resistance exercises to the point of failure, using either light weights for many reps or heavy weights for fewer reps, you will get the same microvascular benefits. Focus on reaching failure rather than obsessing over the specific weight on the bar.

Consuming a higher variety of protein sources (from 8 major food groups) at their respective appropriate quantity windows is inversely associated with the risk of new-onset hypertension.

To lower your risk of high blood pressure, focus on eating a wide variety of protein sources—such as grains, red meat, poultry, fish, eggs, and legumes—rather than just increasing total protein. Ensure you are eating these sources in moderate, balanced amounts, as both too little and too much of specific types can increase risk. Aim for a diverse diet that includes small portions from each of these major protein groups.

There is no single 'appropriate' amount for all protein sources; each source (red meat, poultry, fish, etc.) has a unique non-linear relationship with hypertension risk, requiring source-specific quantity windows.

Don't just focus on hitting a total protein number. Pay attention to what kind of protein you are eating. Some sources like red meat and poultry may increase risk if eaten in excess, while others like legumes and eggs may offer protection. A balanced mix of moderate amounts from various sources is key.

The statistical method used to analyze the relationship between muscle hypertrophy and strength gain significantly alters the observed correlation, with hierarchical linear modeling (HLM) revealing stronger within-individual associations than between-subject correlations or ANCOVA.

If you are designing a study or interpreting research on muscle growth and strength, do not rely on simple between-subject correlations (comparing Person A to Person B). Use within-subject analyses (like Hierarchical Linear Modeling) to see how an individual's growth relates to their strength gain. For practitioners, this means individual responses vary wildly; some people get strong without growing much, and some grow without getting proportionally stronger. Do not assume muscle size is the sole driver of strength.

Very low-calorie diets (VLCD) are suitable for short-term use in specific clinical populations, such as those with Type 2 Diabetes (T2D), to improve glycemic control and cardiovascular risk factors, but are not recommended for long-term use or for older adults at risk of sarcopenia.

If you have Type 2 Diabetes, a very low-calorie diet might help your blood sugar and weight quickly, but only under doctor supervision and for a short time. Do not use this if you are older and worried about muscle loss.

GLP-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk and body weight in obese patients with pre-existing cardiovascular disease, regardless of diabetes status, by modulating metabolic pathways, reducing inflammation, and slowing gastric emptying.

If you are overweight or obese and have existing heart disease, GLP-1 receptor agonists like semaglutide are a proven treatment to lower your risk of heart attacks, strokes, and death from heart causes, even if you don't have diabetes. These drugs work by mimicking a hormone that helps control blood sugar, reduces appetite, and slows digestion. While they are injections, their ability to protect your heart and reduce weight makes them a critical tool for secondary prevention. Always discuss with your doctor if this is right for you, especially regarding side effects and dosing.

Obesity pharmacotherapies, specifically high-dose semaglutide and tirzepatide, are highly effective for long-term weight management (>10% loss at 6 months) but remain dramatically underprescribed due to clinician knowledge gaps, safety concerns, and insurance coverage limitations.

If you qualify for obesity pharmacotherapy, discuss semaglutide or tirzepatide with your provider. While highly effective (>10% weight loss), access is limited by insurance. Ask about coverage options, especially if you have cardiovascular risk, as recent policy changes may improve access.

Overreliance on BMI as the sole metric for obesity management hinders clinical implementation and confuses clinicians, leading to suboptimal care; waist circumference is a more useful tool for assessing health risk.

Ask your clinician to measure your waist circumference, not just your BMI. This provides better insight into your cardiovascular risk and helps prioritize obesity management interventions.

Bioelectrical Impedance Spectroscopy (BIS) is recommended as a feasible, noninvasive, and inexpensive method to assess body fat mass and visceral fat, explaining 80-90% of variance in fat mass compared to gold standards.

Bioelectrical Impedance Spectroscopy (BIS) is recommended for obesity trials as a feasible alternative to expensive imaging. It provides a good estimate of body fat and visceral fat, explaining up to 90% of the variance compared to gold-standard methods like DXA.

Calculated Resting Energy Expenditure (REE) using the Mifflin-St. Jeor equation is recommended over direct calorimetry for large clinical trials due to feasibility, though direct measurement is suggested if resources allow.

For large obesity trials, calculating Resting Energy Expenditure (REE) using the Mifflin-St. Jeor equation is the recommended standard. It is feasible, cost-effective, and correlates well with direct calorimetric measurements.

Metabolic surgery provides superior short-term remission of type 2 diabetes and greater weight loss compared to pharmacotherapy alone, but long-term remission rates decline significantly over time.

Metabolic surgery (like gastric bypass or sleeve gastrectomy) is currently the most effective treatment for obesity and Type 2 Diabetes, offering significantly greater weight loss and diabetes remission rates than medication alone. However, these benefits tend to fade over several years, meaning surgery is not a permanent 'cure' but a powerful tool that often requires ongoing medical management to maintain results.

A multimodal treatment approach combining metabolic surgery with adjuvant pharmacotherapy (specifically GLP-1 agonists or other anti-obesity drugs) is superior to surgery alone for maintaining long-term glycemic control and remission.

For the best long-term results, Type 2 Diabetes treatment should combine metabolic surgery with ongoing medication (like GLP-1 agonists). This multimodal approach significantly increases the chance of keeping diabetes in remission compared to surgery or medication alone, addressing the fact that surgical benefits can fade over time.

Pregnant women with obesity exhibit significantly lower physical activity levels compared to general population guidelines, contributing to lower total daily energy expenditure.

Obese pregnant women tend to be significantly less active than recommended, with the vast majority classified as sedentary. Increasing physical activity could be a key intervention to improve energy balance and prevent excessive weight gain.

Physical activity improves metabolic health and reduces blood glucose levels independently of weight loss and insulin signaling pathways.

You do not need to lose weight to get the metabolic benefits of exercise. Even if your weight stays the same, physical activity helps your muscles take up glucose without relying on insulin, which is crucial for preventing or managing type 2 diabetes and metabolic syndrome. Focus on consistency rather than just the number on the scale.

Obesity and metabolic disease are driven by a misalignment between behaviors (feeding/fasting rhythms, physical activity) and tissue functions (organ clocks), regulated by circadian molecular clocks in the brain and periphery.

Your body's organs operate on a 24-hour schedule. Try to align your eating and sleeping times with your natural circadian rhythm. Eating large meals late at night or irregularly can disrupt the internal clocks in your liver, muscle, and fat, leading to metabolic issues. Consistent meal times and adequate sleep support better metabolic health.